loading
Celldex Therapeutics Inc stock is traded at $19.93, with a volume of 673.96K. It is down -0.25% in the last 24 hours and down -1.87% over the past month.
See More
Previous Close:
$19.98
Open:
$19.83
24h Volume:
673.96K
Relative Volume:
0.82
Market Cap:
$1.33B
Revenue:
$9.98M
Net Income/Loss:
$-154.08M
P/E Ratio:
-7.7248
EPS:
-2.58
Net Cash Flow:
$-159.66M
1W Performance:
+1.48%
1M Performance:
-1.87%
6M Performance:
-39.97%
1Y Performance:
-52.51%
1-Day Range:
Value
$19.51
$20.19
1-Week Range:
Value
$19.48
$21.02
52-Week Range:
Value
$18.95
$47.00

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name
Name
Celldex Therapeutics Inc
Name
Phone
908-200-7500
Name
Address
53 FRONTAGE ROAD, HAMPTON
Name
Employee
0
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
CLDX's Discussions on Twitter

Compare CLDX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CLDX
Celldex Therapeutics Inc
19.93 1.33B 9.98M -154.08M -159.66M -2.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-20-25 Initiated Morgan Stanley Overweight
Feb-13-25 Initiated UBS Buy
Oct-07-24 Initiated Citigroup Buy
Sep-30-24 Initiated Goldman Neutral
Sep-27-24 Downgrade Wolfe Research Outperform → Peer Perform
Jun-18-24 Initiated Stifel Buy
Jun-11-24 Initiated Wolfe Research Outperform
Dec-20-23 Initiated TD Cowen Outperform
Nov-10-23 Upgrade Wells Fargo Underweight → Equal Weight
Aug-22-23 Initiated Wells Fargo Underweight
Sep-17-21 Initiated Jefferies Buy
Sep-10-21 Initiated SVB Leerink Outperform
Jul-22-21 Initiated Guggenheim Buy
Feb-21-20 Initiated Cantor Fitzgerald Overweight
Aug-01-17 Resumed H.C. Wainwright Buy
Nov-07-16 Initiated Aegis Capital Buy
Mar-08-16 Downgrade Jefferies Buy → Hold
Mar-07-16 Downgrade Guggenheim Buy → Neutral
Mar-07-16 Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16 Downgrade Wedbush Outperform → Neutral
Mar-01-16 Initiated H.C. Wainwright Buy
Aug-11-15 Reiterated Brean Capital Buy
Aug-11-15 Reiterated Oppenheimer Outperform
Aug-11-15 Reiterated ROTH Capital Buy
Jun-02-15 Reiterated WBB Securities Strong Buy
Nov-17-14 Reiterated ROTH Capital Buy
Mar-04-14 Reiterated Oppenheimer Outperform
Jul-08-13 Reiterated Cantor Fitzgerald Buy
Mar-08-13 Reiterated Cantor Fitzgerald Buy
Feb-26-13 Reiterated Oppenheimer Outperform
Jan-10-13 Reiterated Cantor Fitzgerald Buy
Oct-02-12 Reiterated Oppenheimer Outperform
Sep-14-12 Reiterated Cantor Fitzgerald Buy
View All

Celldex Therapeutics Inc Stock (CLDX) Latest News

pulisher
Mar 27, 2025

Global Cholera Vaccines Market Business Outlook ,Growth - openPR

Mar 27, 2025
pulisher
Mar 23, 2025

Hive Of ActivityCelldex To Report Long-term Results Of Urticaria Drug - RTTNews

Mar 23, 2025
pulisher
Mar 23, 2025

Why Celldex Deserves Your Attention? - RTTNews

Mar 23, 2025
pulisher
Mar 20, 2025

7 Analysts Have This To Say About Celldex Therapeutics - Benzinga

Mar 20, 2025
pulisher
Mar 20, 2025

Celldex a new overweight at Morgan Stanley on urticaria candidate - Seeking Alpha

Mar 20, 2025
pulisher
Mar 20, 2025

This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Mar 20, 2025
pulisher
Mar 20, 2025

Morgan Stanley Initiates Coverage of Celldex Therapeutics (CLDX) with Overweight Recommendation - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

MS starts coverage on Celldex, bullish view on company's skin disease treatment - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Morgan Stanley Initiates Celldex Therapeutics at Overweight With $46 Price Target -March 20, 2025 at 07:14 am EDT - Marketscreener.com

Mar 20, 2025
pulisher
Mar 18, 2025

Personalized Cancer Vaccines Market | Growth, Innovations & - openPR

Mar 18, 2025
pulisher
Mar 14, 2025

Strategies for Managing Chronic Spontaneous Urticaria - Medscape

Mar 14, 2025
pulisher
Mar 11, 2025

A better buy-in window may exist right now for Celldex Therapeutics Inc (CLDX) - SETE News

Mar 11, 2025
pulisher
Mar 06, 2025

Celldex Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 06, 2025
pulisher
Mar 05, 2025

The Goldman Sachs Group Issues Pessimistic Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock Price - Armenian Reporter

Mar 05, 2025
pulisher
Mar 04, 2025

Celldex’s CDX-622 shows promise for inflammatory disorders - BioWorld Online

Mar 04, 2025
pulisher
Mar 04, 2025

Celldex Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

Mar 04, 2025
pulisher
Mar 04, 2025

CLDXCelldex Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Mar 04, 2025
pulisher
Mar 04, 2025

H.C. WAINWRIGHT MAINTAINS BUY RATING, $80 TARGET ON CELLDEX STOCK - Investing.com UK

Mar 04, 2025
pulisher
Mar 04, 2025

Celldex Therapeutics (NASDAQ:CLDX) Price Target Lowered to $36.00 at The Goldman Sachs Group - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

UBS Initiates Coverage of Celldex Therapeutics (CLDX) with Buy Recommendation - MSN

Mar 03, 2025
pulisher
Mar 03, 2025

Celldex Therapeutics Reports Positive Preclinical Data For Inflammation Drug - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

Can Celldex's Dual-Mechanism CDX-622 Transform Inflammatory Disease Treatment? - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

Celldex Therapeutics’ (CLDX) Buy Rating Reiterated at HC Wainwright - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

Celldex announces data from Phase 2 barzolvolimab studies - MSN

Mar 02, 2025
pulisher
Mar 02, 2025

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting - The Manila Times

Mar 02, 2025
pulisher
Mar 01, 2025

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 - The Manila Times

Mar 01, 2025
pulisher
Mar 01, 2025

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients ... - Enid News & Eagle

Mar 01, 2025
pulisher
Mar 01, 2025

Can Celldex's Urticaria Treatment Transform Patient Lives? Phase 2 Data Shows 95% Quality of Life Improvement - StockTitan

Mar 01, 2025
pulisher
Mar 01, 2025

Celldex Therapeutics (NASDAQ:CLDX) Receives Buy Rating from HC Wainwright - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Celldex Therapeutics (NASDAQ:CLDX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month LowWhat's Next? - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics - Benzinga

Feb 28, 2025
pulisher
Feb 28, 2025

Celldex Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Feb 28, 2025
pulisher
Feb 28, 2025

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - The Manila Times

Feb 28, 2025
pulisher
Feb 28, 2025

Celldex: Q4 Earnings Snapshot - The Washington Post

Feb 28, 2025
pulisher
Feb 27, 2025

Celldex Therapeutics Advances Pipeline Amid Financial Challenges - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Celldex reports Q4 EPS (71c), consensus (71c) - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates - MSN

Feb 27, 2025
pulisher
Feb 27, 2025

Celldex: Q4 Earnings Snapshot -February 27, 2025 at 04:33 pm EST - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Celldex Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Celldex Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Can Celldex's $725M War Chest and Promising Clinical Data Deliver Returns for Investors? - StockTitan

Feb 27, 2025
pulisher
Feb 25, 2025

Celldex stock touches 52-week low at $20.86 amid market challenges - Investing.com India

Feb 25, 2025
pulisher
Feb 22, 2025

Celldex Therapeutics Inc (CLDX) Recovers 7.41% From Low: Are We There Yet? - Stocks Register

Feb 22, 2025
pulisher
Feb 22, 2025

Celldex Therapeutics (CLDX) Projected to Post Earnings on Monday - Defense World

Feb 22, 2025
pulisher
Feb 21, 2025

Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential - MSN

Feb 21, 2025
pulisher
Feb 21, 2025

Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX-622 - Wiley Online Library

Feb 21, 2025
pulisher
Feb 20, 2025

Chronic Spontaneous Urticaria Market to Register - GlobeNewswire

Feb 20, 2025
pulisher
Feb 20, 2025

Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire

Feb 20, 2025
pulisher
Feb 20, 2025

Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.

Feb 20, 2025

Celldex Therapeutics Inc Stock (CLDX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Celldex Therapeutics Inc Stock (CLDX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Martin Samuel Bates
SVP AND CFO
Jun 14 '24
Option Exercise
10.16
20,169
204,990
45,297
Martin Samuel Bates
SVP AND CFO
Jun 14 '24
Sale
35.42
17,172
608,315
28,125
Crowley Elizabeth
SR. VP & CPDO
Jun 14 '24
Option Exercise
10.38
30,000
311,400
39,074
Crowley Elizabeth
SR. VP & CPDO
Jun 14 '24
Sale
34.87
30,000
1,045,962
9,074
Young Diane C.
SVP, CHIEF MEDICAL OFFICER
Jun 11 '24
Option Exercise
2.71
15,000
40,650
17,115
Crowley Elizabeth
SR. VP & CPDO
Jun 07 '24
Option Exercise
9.70
15,000
145,474
24,074
Crowley Elizabeth
SR. VP & CPDO
Jun 07 '24
Sale
35.06
15,000
525,873
9,074
Young Diane C.
SVP, CHIEF MEDICAL OFFICER
Jun 07 '24
Sale
35.26
45,000
1,586,844
2,115
Jimenez Freddy A.
SVP & GENERAL COUNSEL
Jun 05 '24
Option Exercise
10.38
9,540
99,025
35,464
Heath-Chiozzi Margo
SVP OF REGULATORY AFFAIRS
Jun 03 '24
Option Exercise
10.25
64,658
662,575
71,752
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
Cap:     |  Volume (24h):